Lueza, Béranger
Aupérin, Anne
Rigaud, Charlotte
Gross, Thomas G.
Pillon, Marta
Delgado, Rafael F.
Uyttebroeck, Anne
Amos Burke, G. A. http://orcid.org/0000-0003-2671-9972
Zsíros, József
Csóka, Monika
Simonin, Mathieu
Patte, Catherine
Minard-Colin, Véronique
Bonastre, Julia http://orcid.org/0000-0001-9884-0072
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma
https://doi.org/10.1007/s10198-023-01581-y
Funding for this research was provided by:
Ministère des Affaires Sociales, de la Santé et des Droits des Femmes
Article History
Received: 15 April 2022
Accepted: 13 March 2023
First Online: 14 April 2023
Declarations
:
: Anne Aupérin: Research funding (recipient: institution): F Hoffmann- La Roche- Genentec. G.A. Amos Burke: Consulting or advisory role with compensation for the institution: F Hoffmann- La Roche, Janssen, Novartis, Takeda. Catherine Patte: Research funding (recipient: institution): F Hoffmann- La Roche. Véronique Minard-Colin: Consulting or advisory role with compensation for the institution: Roche, BMS, Novartis; Research funding (recipient: institution): F Hoffmann- La Roche, BMS. Julia Bonastre: Consulting or advisory role with individual compensation: Astellas, BMS, MSD; Travel expenses: BMS. The other authors have no conflict of interest to declare.